Novo Nordisk and Novartis Halt Heart Drug Trials After Trial Failures
Novo Nordisk halted two trials of its heart disease drug ziltivekimab after data showed a low likelihood of success, following a previous trial failure. Meanwhile, Novartis reported its heart drug pelacarsen failed to reduce cardiovascular deaths, heart attacks, and strokes despite lowering lipoprotein(a) levels. These setbacks raise questions about the effectiveness of Lp(a)-lowering therapies. Both companies continue other studies, with Novartis focusing on treatments for autoimmune diseases and genetic muscle disorders.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is negative (38/100). Lens Score 44/100.
Outlets measured: theprint, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (38–38/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 7 Sept, 07:20 am. Other outlets followed.
- 1